Osiris Therapeutics (OSIR) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
Osiris Therapeutics Announces First Quarter 2015 Financial Results
May 8, 2015 8:00 AM EDTCOLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today its financial results for the first quarter of 2015.
Highlights and Recent Developments
Increased product revenue for the quarter to $21.0 million - a 109% increase over Q1 2014. Gross margin... More


